Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06246916
Title A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.